Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2015
|
| In: |
The lancet. Haematology
Year: 2015, Jahrgang: 2, Heft: 12, Pages: e516-e527 |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(15)00197-0 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S2352-3026(15)00197-0
|
| Verfasserangaben: | Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J. Jakubowiak, Marc S. Raab, Thierry Facon, Prof Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, Sagar Lonial, on behalf of the 1703 study investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 154548385X | ||
| 003 | DE-627 | ||
| 005 | 20220813024206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 160728s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2352-3026(15)00197-0 |2 doi | |
| 035 | |a (DE-627)154548385X | ||
| 035 | |a (DE-576)475483855 | ||
| 035 | |a (DE-599)BSZ475483855 | ||
| 035 | |a (OCoLC)1340926442 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Richardson, Paul G. |e VerfasserIn |0 (DE-588)1073660222 |0 (DE-627)829311114 |0 (DE-576)435237594 |4 aut | |
| 245 | 1 | 0 | |a Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma |b final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study |c Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J. Jakubowiak, Marc S. Raab, Thierry Facon, Prof Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, Sagar Lonial, on behalf of the 1703 study investigators |
| 264 | 1 | |c December 2015 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.07.2016 | ||
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Haematology |d London [u.a.] : Elsevier, 2014 |g 2(2015), 12, Seite e516-e527 |h Online-Ressource |w (DE-627)810540304 |w (DE-600)2802056-X |w (DE-576)420435689 |x 2352-3026 |7 nnas |a Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study |
| 773 | 1 | 8 | |g volume:2 |g year:2015 |g number:12 |g pages:e516-e527 |g extent:12 |a Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2352-3026(15)00197-0 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20160728 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |e 910000PR124052460 |k 0/910000/ |p 5 | ||
| 999 | |a KXP-PPN154548385X |e 293496406X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma","subtitle":"final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma"}],"note":["Gesehen am 28.07.2016"],"origin":[{"dateIssuedDisp":"December 2015","dateIssuedKey":"2015"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J. Jakubowiak, Marc S. Raab, Thierry Facon, Prof Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, Sagar Lonial, on behalf of the 1703 study investigators"]},"recId":"154548385X","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"810540304","id":{"eki":["810540304"],"zdb":["2802056-X"],"issn":["2352-3026"]},"title":[{"title":"The lancet","title_sort":"lancet","partname":"Haematology"}],"note":["Gesehen am 27.11.14"],"origin":[{"dateIssuedDisp":"2014-","dateIssuedKey":"2014","publisher":"Elsevier","publisherPlace":"London [u.a.]"}],"pubHistory":["1.2014 -"],"disp":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation studyThe lancet. Haematology","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"titleAlt":[{"title":"The lancet <London> / Haematology"}],"part":{"text":"2(2015), 12, Seite e516-e527","issue":"12","pages":"e516-e527","year":"2015","volume":"2","extent":"12"}}],"id":{"doi":["10.1016/S2352-3026(15)00197-0"],"eki":["154548385X"]},"person":[{"role":"aut","given":"Paul G.","display":"Richardson, Paul G.","family":"Richardson"},{"given":"Marc-Steffen","role":"aut","display":"Raab, Marc-Steffen","family":"Raab"}],"language":["eng"]} | ||
| SRT | |a RICHARDSONELOTUZUMAB2015 | ||